Drug Profile
BMS 986371
Alternative Names: BMS-986371; CC-99677Latest Information Update: 26 Oct 2023
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Anti-inflammatories
- Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ankylosing spondylitis; Inflammation
Most Recent Events
- 26 Oct 2023 Discontinued - Phase-I for Inflammation (In volunteers) in USA, United Kingdom (PO) prior to October 2023 (Bristol-Myers Squibb pipeline, October 2023)
- 26 Oct 2023 Discontinued - Phase-II for Ankylosing spondylitis in Turkey, Spain, Poland, Romania, Poland, Czech Republic, China, USA, Germany (PO) prior to October 2023 (Bristol-Myers Squibb pipeline, October 2023)
- 15 Feb 2023 Celgene terminates a phase-II clinical trials in Ankylosing spondylitis due to lack of efficacy in Germany, Turkey, Spain, Romania, Poland, Czech Republic, China, USA (PO) (NCT04947579)